Indian pharma regulation, a shift in paradrigm

Preview:

Citation preview

Indian Pharmaceutical RegulationsA current regulatory overview

Prepared by: Sambhujyoti Das

2

Indian Pharmaceutical Sector – An Overview

One of the high performing knowledge based segments of the manufacturing sector.• The ‘organised’ sector of India’s pharmaceutical industry consists of about 300 companies.

• The total sector is estimated at nearly 20,000 businesses.

• 400 + bulk drugs are produced.

• Producing high quality generic medicines that are sold around the world.

• Supplying 20% (value wise) of the global market for generic medicines.

• Exporting medicine to over 200 countries.

• Total review around US$ 20 bn +.

• Compound annual growth rate of 20 percent.

3

+

Regulatory Framework

As per Drugs & Cosmetic Act 1940.

4

Proposed New Drug Regulatory System

• Formation of Central Drug Authority (CDA) in January 2007.

• The organisational structure of CDA would be similar to US FDA.

• It would be strong, well equipped, empowered, independent and professionally managed.

• It would facilitate upgradation of the national drugs regulator, uniformity of licencing and

improvement in drug regulations.

• Strict enforcement of GMP standards to builds up trust of its clients and the obligation on

the regulatory bodies.

• Training and technical capacity building and provide necessary know how to help

manufacturer with GMP compliance.

• Focus on inspection, pharmacovigilance and drug enforcement activities.

5

Proposed New Drug Regulatory System

CDA(Central Drug

Administration)

CDSCO(Central Drug Standard Control

Organization)

SDRA(State Drug Regulatory Agency)

Central independent body under Ministry of Health &

Family Welfare

Central body

State entity

6

Roles and Responsibilities

7

Regulatory Reforms

MANPOWER Creation of new

posts. Capability & skill

development through trainings.

Optimum utilization of current staff.

INFRASTRUCTURE Expansion of zonal &

sub zonal offices. Strengthening of

central & state drug testing labs.

Expansion of current pharmacovigilance programmes.

INSPECTIONS CDA grants Mfg. license.

Establish surveillance against suspected persons.

Strict adherence to scheduled standards.

8

Regulatory Reforms

FINANCE

Additional fund to CDA INDEPENDENT

REGULATOR Efficient, strong & effective CDA.

Autonomous organization under DCGI.TRANSPARENCY & 3RD

PARTY OVERSIGHT Traceable distribution

channel. Awareness program to

customers. Drug information on

internet. Press release against

noncomplying products and organizations.

ADE reporting through internet.

Questions and discussion

THANK YOU

Recommended